Fruquintinib in Combination With Sintilimab and CAPEOX as First-line Treatment for G/GEJ Cancer
Condition(s):Metastatic Gastroesophageal Junction AdenocarcinomaLast Updated:March 26, 2024Recruiting
Hide Studies Not Open or Pending
Condition(s):Metastatic Gastroesophageal Junction AdenocarcinomaLast Updated:March 26, 2024Recruiting
Condition(s):Dorsal Scapular Nerve EntrapmentLast Updated:March 27, 2024Not yet recruiting
Condition(s):Advanced Pancreatic CancerLast Updated:March 26, 2024Not yet recruiting
Condition(s):Brain InjuriesLast Updated:March 26, 2024Completed
Condition(s):Lung CancerLast Updated:March 26, 2024Recruiting
Condition(s):Chronic Kidney Disease; SarcopeniaLast Updated:March 26, 2024Not yet recruiting
Condition(s):Lower Extremity LymphedemaLast Updated:March 25, 2024Recruiting
Condition(s):Rotator Cuff InjuriesLast Updated:March 25, 2024Recruiting
Condition(s):HealthyLast Updated:March 25, 2024Recruiting
Condition(s):HealthyLast Updated:March 25, 2024Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.